Literature Review: Minoxidil for Androgenetic Alopecia

    March 2026 in “ International Society of Hair Restoration Surgery ”
    Martha Gabriela Contreras
    Studysummary This abstract does not report specific findings but notes that topical minoxidil, available in 2% and 5% formulations, is widely used and FDA-approved for treating androgenetic alopecia in both men and women, with a strong safety profile.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Short-Term Topical Minoxidil Use Associated With Acute Central Serous Chorioretinopathy: A Case Report Case Reports in Ophthalmology · 2025
    2. Acute Central Serous Chorioretinopathy Following Topical Minoxidil Use for Androgenic Alopecia: A Case Report TNOA journal of ophthalmic science and research · 2023
    3. Retinal Artery Occlusion as a Probable Idiosyncratic Reaction to Topical Minoxidil: A Case Report Journal of Medical Case Reports · 2021
    4. Minoxidil Induced Central Serous Chorioretinopathy Treated with Oral Eplerenone – A Case Report BMC Ophthalmology · 2020
    5. Central Chorioretinopathy Associated with Topical Use of Minoxidil 2% for Treatment of Baldness Cutaneous and Ocular Toxicology · 2011
    6. Minoxidil: Mechanisms of Action on Hair Growth British Journal of Dermatology · 2004